Flu Season Update: A(H3N2) Dominance and the Ongoing Evolution of Influenza Viruses
As winter descends across the Northern Hemisphere, concerns about respiratory illnesses, particularly influenza, are rising. While the initial reports from France indicated a predominance of the A(H3N2) subtype over A(H1N1)pdm09, a broader seem at global surveillance data reveals a more complex picture of circulating influenza strains. Understanding the dynamics of these viruses, their genetic evolution, and the effectiveness of current vaccines is crucial for public health preparedness and individual protection. This article provides an update on the current influenza landscape, drawing on the latest surveillance data and scientific research.
Influenza viruses are notorious for their ability to mutate, leading to seasonal epidemics and, occasionally, pandemics. There are four types of influenza viruses – A, B, C, and D – but influenza A and B viruses are primarily responsible for seasonal flu outbreaks in the United States, and globally. The Centers for Disease Control and Prevention (CDC) explains that influenza A viruses are the only ones known to cause pandemics, which can occur when a novel virus emerges against which the population has little to no immunity.
Understanding Influenza A Subtypes: H1N1pdm09 and H3N2
Influenza A viruses are classified into subtypes based on two proteins on their surface: hemagglutinin (H) and neuraminidase (N). There are 18 different HA subtypes and 11 different NA subtypes, leading to numerous possible combinations. Currently, A(H1N1) and A(H3N2) are the subtypes most commonly circulating among humans. The A(H1N1)pdm09 virus, often referred to as “2009 H1N1,” emerged in 2009 and has continued to circulate seasonally, undergoing genetic and antigenic changes. Similarly, A(H3N2) viruses also exhibit ongoing genetic and antigenic drift.
The initial reports suggesting a dominance of A(H3N2) align with observations from previous seasons where this subtype has often been responsible for more severe illness, particularly among the elderly and those with underlying health conditions. However, the situation is dynamic, and co-circulation of both A(H1N1)pdm09 and A(H3N2) is common, as highlighted in a 2019 report from the World Health Organization (WHO) European Region. This report detailed the co-circulation of these subtypes between October 2018 and February 2019, emphasizing the regional variations in their prevalence.
Recent Genomic Surveillance and Viral Evolution
Recent research focusing on the genomic surveillance of influenza A viruses provides valuable insights into their evolution and diversity. A study published in ScienceDirect analyzed the genomes of 128 A/pdm09 H1N1 and 113 A/H3N2 clinical isolates, revealing distinct epidemic patterns across different influenza seasons. The study also noted a decline in influenza cases during the COVID-19 pandemic, likely due to the widespread implementation of public health measures such as mask-wearing and social distancing.
Understanding the genetic evolution of these viruses is critical for predicting which strains are likely to dominate in future seasons and for developing effective vaccines. Influenza viruses can undergo both antigenic drift – small, gradual changes in their surface proteins – and antigenic shift – sudden, major changes that can lead to the emergence of novel strains. Antigenic shift often occurs when two different influenza viruses infect the same host and exchange genetic material, a process known as reassortment.
Vaccine Effectiveness and Current Recommendations
Vaccination remains the most effective way to protect against influenza. Current influenza vaccines are designed to protect against multiple strains, including A(H1N1)pdm09 and A(H3N2). According to the WHO, recent interim vaccine effectiveness (VE) estimates indicate that the current vaccine is effective at preventing influenza virus infection, particularly by A(H1N1)pdm09 viruses, especially in children. However, vaccine effectiveness can vary depending on the match between the vaccine strains and the circulating strains, as well as individual factors such as age and immune status.
Public health officials recommend that everyone 6 months and older receive an annual influenza vaccine. Vaccination is particularly important for individuals at high risk of complications from influenza, including young children, pregnant women, older adults, and people with chronic health conditions. In addition to vaccination, other preventive measures, such as frequent handwashing, covering coughs and sneezes, and staying home when sick, can help to reduce the spread of influenza.
The Impact of COVID-19 on Influenza Circulation
The COVID-19 pandemic significantly altered the landscape of respiratory virus circulation. The implementation of non-pharmaceutical interventions, such as lockdowns, mask mandates, and social distancing, led to a dramatic decrease in influenza cases during the 2020-2021 and 2021-2022 influenza seasons. However, as these measures were relaxed, influenza viruses began to re-emerge, leading to concerns about potential co-circulation of influenza and SARS-CoV-2, the virus that causes COVID-19.
The re-emergence of influenza highlights the importance of continued surveillance and vaccination efforts. Co-infection with influenza and SARS-CoV-2 can lead to more severe illness and increased risk of hospitalization. It is crucial for individuals to protect themselves against both viruses through vaccination and other preventive measures.
Looking Ahead: Ongoing Surveillance and Preparedness
The influenza landscape is constantly evolving, and ongoing surveillance is essential for tracking the spread of viruses, monitoring their genetic changes, and assessing vaccine effectiveness. The WHO Global Influenza Surveillance and Response System (GISRS) plays a critical role in this effort, coordinating surveillance activities around the world and providing data to inform vaccine development.
Continued investment in influenza research and surveillance is crucial for preparing for future pandemics. Developing fresh and improved vaccines, as well as antiviral medications, is essential for mitigating the impact of influenza on public health. Strengthening public health infrastructure and improving global coordination are vital for responding effectively to emerging infectious disease threats.
The next key checkpoint for influenza updates will be the release of updated vaccine effectiveness data from the CDC and WHO in early March 2026. Stay informed about the latest developments and consult with your healthcare provider for personalized recommendations.
Disclaimer: This article provides general information about influenza and should not be considered medical advice. Please consult with a healthcare professional for diagnosis and treatment of any medical condition.
Do you have questions about influenza or the current flu season? Share your thoughts and concerns in the comments below. And please, share this article with your friends and family to help spread awareness about influenza prevention.
Related reading